Wave Life Sciences price to book ratio WVE

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 1.4×
10-year median: 6.3×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.4× to 31.5×
Peer median: 2.3×

Wave Life Sciences' price to book ratio is 1.4× as of Oct 23, 2026.

That is below its ten-year median of 6.3×, lower than on 100% of days in the last ten years.

Over that time it ranged from 1.4× in Oct 2026 to 31.5× in Jul 2024.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.4×	1.4×	21.4×
2025	23.9×	4.1×	23.9×
2024	13.9×	13.9×	31.5×
2023	n/m a value too high to mean anything
2022	12.7×	3.2×	14.6×
2021	6.2×	3.6×	14.9×
2020	3.5×	2.1×	18.5×
2019	4.7×	3.3×	21.4×
2018	11.7×	5.6×	13.7×
2017	5.9×	2.5×	6.6×
2016	4.1×	1.8×	6.1×

Against its peers

Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.

Company	Price to book ratio
WVEWave Life Sciences	1.4×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	2.7×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
COLLCollegium Pharmaceutical	2.4×
ARVNArvinas	0.8×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Wave Life Sciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.